Lipid-altering changes and pleiotropic effects of atorvastatin in patients with hypercholesterolemia

被引:34
|
作者
Sakabe, K [1 ]
Fukuda, N [1 ]
Wakayama, K [1 ]
Nada, T [1 ]
Shinohara, H [1 ]
Tamura, Y [1 ]
机构
[1] Natl Zentsuji Hosp, Dept Cardiol & Clin Res, Kagawa 7658507, Japan
来源
AMERICAN JOURNAL OF CARDIOLOGY | 2004年 / 94卷 / 04期
关键词
D O I
10.1016/j.amjcard.2004.04.067
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In this prospective study, we found beneficial short-term effects from atorvastatin therapy, including effects on low-density lipoprotein subfractions and remnant-like lipoprotein particle cholesterol, antioxidant effects, and alterations in endothelial function that may be important in early benefit from statin therapy; some effects would support much earlier benefit than previously reported. We also found long-term effects of atorvastatin, including decreased plasminogen activator inhibitor type-1 and additional significant alterations in low-density lipoprotein subfractions and endothelial function, supporting benefits from continuous long-term atorvastatin therapy beyond early reversal of hypercholesterolemia. (C) 2004 by Excerpta Medica, Inc.
引用
收藏
页码:497 / 500
页数:4
相关论文
共 50 条
  • [41] Atorvastatin's different doses lipid lowering, pleiotropic and plaque stability effects
    Beridze, M
    Kipshidze, N
    Kakauridze, N
    ATHEROSCLEROSIS SUPPLEMENTS, 2003, 4 (02) : 161 - 162
  • [42] Overview of prevention and treatment of atherosclerosis with lipid-altering therapy for pharmacy directors
    Davidson, Michael H.
    AMERICAN JOURNAL OF MANAGED CARE, 2007, 13 (10): : S260 - S269
  • [43] Evidence for pleiotropic effects of atorvastatin in patients with congestive heart failure
    Tousoulis, Dimitris
    Antomades, Charalambos
    Marinou, Kiriakoula
    Vavuranalkis, Emmanouil
    Brili, Stella
    Papageorgiou, Nikos
    Toutouzas, Kostas
    Tsioufis, Costas
    Trikas, A.
    Stefanadis, Christodoulos
    CIRCULATION, 2007, 116 (16) : 332 - 332
  • [44] Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk
    Farnier, Michel
    CURRENT CARDIOLOGY REPORTS, 2016, 18 (07)
  • [45] Atherosclerotic Cardiovascular Disease in Women: Providing Protection With Lipid-altering Agents
    Hiles, Megan
    Simmons, Ashley
    Hilleman, Daniel
    Gibson, Cheryl A.
    Backes, James M.
    CLINICAL THERAPEUTICS, 2023, 45 (11) : 1127 - 1136
  • [46] Model-based development of gemcabene, a new lipid-altering agent
    Jaap W. Mandema
    David Hermann
    Wenping Wang
    Tim Sheiner
    Mark Milad
    Rebecca Bakker-Arkema
    Daniel Hartman
    The AAPS Journal, 7
  • [47] Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease
    Barrios, V
    Amabile, N
    Paganelli, F
    Chen, JW
    Allen, C
    Johnson-Levonas, AO
    Massaad, R
    Vandormael, K
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2005, 59 (12) : 1377 - 1386
  • [48] Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk
    Michel Farnier
    Current Cardiology Reports, 2016, 18
  • [49] Model-based development of gemcabene, a new lipid-altering agent
    Mandema, JW
    Hermann, D
    Wang, WP
    Sheiner, T
    Milad, M
    Bakker-Arkema, R
    Hartman, D
    AAPS JOURNAL, 2005, 7 (03): : E513 - E522
  • [50] Anti-inflammatory effect is an important property of niacin on atherosclerosis beyond its lipid-altering effects
    Yu, Bi-lian
    Zhao, Shui-ping
    MEDICAL HYPOTHESES, 2007, 69 (01) : 90 - 94